Palatin Technologies (PTN)
(Real Time Quote from BATS)
$1.75 USD
-0.07 (-3.95%)
Updated Jun 17, 2024 12:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Price, Consensus and EPS Surprise
PTN 1.75 -0.07(-3.95%)
Will PTN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PTN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTN
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
PTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
Other News for PTN
Palatin starts Phase 2 obesity study of bremelanotide with Zepbound
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Optimistic Outlook on Palatin’s Innovative Obesity Treatment and Phase 2 Trial
Analysts Are Bullish on Top Healthcare Stocks: Repare Therapeutics (RPTX), Palatin Technologies (PTN)
Palatin announces initiation of Phase 2 clinical study of bremelanotide